We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ms
Natalie
Zaremba
Natalie.zaremba@kcl.ac.uk
Dr
Angus
Forbes
angus.forbes@kcl.ac.uk
Diabetes mellitus
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Everyone with type 1 diabetes(T1D) needs to use insulin to control the level of sugar in their body. Most people take injections (jabs) of insulin several times a day; some people use an insulin pump that delivers insulin into the body through a tiny tube called a cannula instead. Unfortunately, almost half of people who take insulin get lumps of fat under their skin that stop the insulin from being absorbed properly. The main risk factors for someone developing fatty lumps under their skin are reusing the same disposable needle for several injections or taking insulin doses in the same body area regularly. Putting insulin into a fatty lump under the skin can cause unexpected high or low blood glucose levels. Over time, having high blood glucose levels increases the risk of sight loss, nerve and kidney damage, heart attack, and stroke. A very low blood glucose level can cause someone to pass out or have a seizure. Without emergency help, a severe low glucose level can be deadly. This study aims to find ways to prevent, detect, and manage fatty lumps, to help people with diabetes avoid the problems these lumps can cause.
We will work together with people with T1D and health professionals to create materials to help people with T1D avoid delivering their insulin into existing fatty lumps. We will also co-create materials explaining the importance of using a fresh needle for every jab and putting insulin doses into different body areas (called ‘injection-site rotation’) to prevent new fatty lumps. We will also get their advice on how to talk about the different ways of checking for fatty lumps. Ultrasound scanning, the same kind of technology that takes a picture of a baby in the womb, could be used to help health professionals find fatty lumps under someone’s skin. However, we do not know how people with T1D and health professionals will get on with using ultrasound scans to check for fatty lumps, so we will ask them about this.
We want to be sure that the work we do is useful for people with T1D as well as for doctors and nurses. We formed a Patient and Public Involvement (PPI) group to get opinions of people with T1D about how we should do this study. Both the PPI group and our patient co-applicant will play key roles in the study, by shaping the materials we use to conduct the study and helping to interpret the study results and outputs. We will pay all the patients who take part for their time. When the study is finished, we will communicate the results widely across patient and professional networks and conferences, and in diabetes magazines, websites and journals.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
For all groups we will exclude those: less than 20 years of age. Unable to provide written informed consent (online or hard copy). Unable to fluently converse in and understand English. Patient participants with T1DM: Participants will be excluded from this study if they exhibit any of the following: severe mental or physical illness, lack a confirmed diagnosis of T1DM, or possess a known cognitive impairment. Participants with a T1DM diagnosis of less than 12 months will be excluded from this study.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by King's College London and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 63829
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
